Kim RB - Search Results

1

Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics.

Katz DA, Carr R, Grimm DR, Xiong H, Holley-Shanks R, Mueller T, Leake B, Wang Q, Han L, Wang PG, Edeki T, Sahelijo L, Doan T, Allen A, Spear BB, Kim RB. Katz DA, et al. Among authors: kim rb. Clin Pharmacol Ther. 2006 Mar;79(3):186-96. doi: 10.1016/j.clpt.2005.11.003. Epub 2006 Feb 17. Clin Pharmacol Ther. 2006. PMID: 16513443

2

OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.

Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. Cvetkovic M, et al. Among authors: kim rb. Drug Metab Dispos. 1999 Aug;27(8):866-71. Drug Metab Dispos. 1999. PMID: 10421612

3

Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity.

Kim RB, Leake B, Cvetkovic M, Roden MM, Nadeau J, Walubo A, Wilkinson GR. Kim RB, et al. J Pharmacol Exp Ther. 1999 Dec;291(3):1204-9. J Pharmacol Exp Ther. 1999. PMID: 10565843

4

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans.

Tirona RG, Leake BF, Merino G, Kim RB. Tirona RG, et al. Among authors: kim rb. J Biol Chem. 2001 Sep 21;276(38):35669-75. doi: 10.1074/jbc.M103792200. Epub 2001 Jul 26. J Biol Chem. 2001. PMID: 11477075 Free article.

5

Identification of functionally variant MDR1 alleles among European Americans and African Americans.

Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR. Kim RB, et al. Clin Pharmacol Ther. 2001 Aug;70(2):189-99. doi: 10.1067/mcp.2001.117412. Clin Pharmacol Ther. 2001. PMID: 11503014

6

Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.

Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB. Dresser GK, et al. Among authors: kim rb. Clin Pharmacol Ther. 2002 Jan;71(1):11-20. doi: 10.1067/mcp.2002.121152. Clin Pharmacol Ther. 2002. PMID: 11823753 Clinical Trial.

7

Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.

Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA. Ekins S, et al. Among authors: kim rb. Mol Pharmacol. 2002 May;61(5):964-73. doi: 10.1124/mol.61.5.964. Mol Pharmacol. 2002. PMID: 11961113

8

Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates.

Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA. Ekins S, et al. Among authors: kim rb. Mol Pharmacol. 2002 May;61(5):974-81. doi: 10.1124/mol.61.5.974. Mol Pharmacol. 2002. PMID: 11961114

9

Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation.

Tirona RG, Leake BF, Wolkoff AW, Kim RB. Tirona RG, et al. Among authors: kim rb. J Pharmacol Exp Ther. 2003 Jan;304(1):223-8. doi: 10.1124/jpet.102.043026. J Pharmacol Exp Ther. 2003. PMID: 12490595

10

Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition.

Ho RH, Leake BF, Roberts RL, Lee W, Kim RB. Ho RH, et al. Among authors: kim rb. J Biol Chem. 2004 Feb 20;279(8):7213-22. doi: 10.1074/jbc.M305782200. Epub 2003 Dec 2. J Biol Chem. 2004. PMID: 14660639 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

417 results

Search Page

Filters